Literature DB >> 20820832

Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents.

A H Diacon1, J S Maritz, A Venter, P D van Helden, K Andries, D F McNeeley, P R Donald.   

Abstract

Evaluation of early bactericidal activity (EBA) by the determination of a fall in viable colony-forming units (CFU) of Mycobacterium tuberculosis in sputum is a first step in the clinical study of new antituberculosis agents. The time to detection (TTD) of growth in liquid media is more sensitive and could substitute for CFU counting on solid media. Overnight sputum samples collected during the evaluation of the novel agent TMC207 in comparison to isoniazid and rifampicin were studied. For the determination of CFU, we incubated 10-fold dilutions of homogenized sputum on selective 7H10 agar. The TTD was measured by incubating decontaminated sputum in the BACTEC MGIT 960 system. The fall in bacillary load over 7 days determined by CFU counting closely matched the prolongation of the TTD in the BACTEC MGIT 960 system. The CFU counts correlated significantly with the TTD. While the ranking of agents and different dosages of TMC207 was similar, the highest dose of TMC207 showed markedly better activity when measured by the TTD than CFU counting when compared to the activity of isoniazid. Automated TTD could augment, or, in future, replace, CFU counting to determine sputum bacillary load in EBA clinical trials pending a more formal evaluation of the correlation of the measurements.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20820832     DOI: 10.1007/s10096-010-1043-7

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  20 in total

Review 1.  Predictive in vitro models of the sterilizing activity of anti-tuberculosis drugs.

Authors:  Denis A Mitchison; Anthony R M Coates
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

2.  The diarylquinoline TMC207 for multidrug-resistant tuberculosis.

Authors:  Andreas H Diacon; Alexander Pym; Martin Grobusch; Ramonde Patientia; Roxana Rustomjee; Liesl Page-Shipp; Christoffel Pistorius; Rene Krause; Mampedi Bogoshi; Gavin Churchyard; Amour Venter; Jenny Allen; Juan Carlos Palomino; Tine De Marez; Rolf P G van Heeswijk; Nacer Lounis; Paul Meyvisch; Johan Verbeeck; Wim Parys; Karel de Beule; Koen Andries; David F Mc Neeley
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

Review 3.  Tuberculosis. Scientific blueprint for tuberculosis drug development.

Authors: 
Journal:  Tuberculosis (Edinb)       Date:  2001       Impact factor: 3.131

4.  Comparison of the Mycobacteria Growth Indicator Tube (MGIT) with radiometric and solid culture for recovery of acid-fast bacilli.

Authors:  G E Pfyffer; H M Welscher; P Kissling; C Cieslak; M J Casal; J Gutierrez; S Rüsch-Gerdes
Journal:  J Clin Microbiol       Date:  1997-02       Impact factor: 5.948

Review 5.  Early bactericidal activity of antituberculosis agents.

Authors:  P R Donald; F A Sirgel; A Venter; D P Parkin; H I Seifart; B W van de Wal; J S Maritz; P B Fourie
Journal:  Expert Rev Anti Infect Ther       Date:  2003-06       Impact factor: 5.091

6.  Sputum Mycobacterium tuberculosis mRNA as a marker of bacteriologic clearance in response to antituberculosis therapy.

Authors:  L Li; C S Mahan; M Palaci; L Horter; L Loeffelholz; J L Johnson; R Dietze; S M Debanne; M L Joloba; A Okwera; W H Boom; K D Eisenach
Journal:  J Clin Microbiol       Date:  2009-11-18       Impact factor: 5.948

7.  Comparison of the mycobacteria growth indicator tube with MB redox, Löwenstein-Jensen, and Middlebrook 7H11 media for recovery of mycobacteria in clinical specimens.

Authors:  A Somoskövi; P Magyar
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

8.  Comparison of two concentrations of NALC-NaOH for decontamination of sputum for mycobacterial culture.

Authors:  R L Peres; E L Maciel; C G Morais; F C K Ribeiro; S A Vinhas; C Pinheiro; R Dietze; J L Johnson; K Eisenach; M Palaci
Journal:  Int J Tuberc Lung Dis       Date:  2009-12       Impact factor: 2.373

Review 9.  Biomarkers for tuberculosis disease activity, cure, and relapse.

Authors:  Robert S Wallis; T Mark Doherty; Phillip Onyebujoh; Mahnaz Vahedi; Hannu Laang; Ole Olesen; Shreemanta Parida; Alimuddin Zumla
Journal:  Lancet Infect Dis       Date:  2009-03       Impact factor: 25.071

10.  Mycobacterium tuberculosis from chronic murine infections that grows in liquid but not on solid medium.

Authors:  Jasvir Dhillon; Douglas B Lowrie; Denis A Mitchison
Journal:  BMC Infect Dis       Date:  2004-11-17       Impact factor: 3.090

View more
  34 in total

1.  The use of an automated quantitative polymerase chain reaction (Xpert MTB/RIF) to predict the sputum smear status of tuberculosis patients.

Authors:  Grant Theron; Lancelot Pinto; Jonny Peter; Hemant Kumar Mishra; Hridesh Kumar Mishra; Richard van Zyl-Smit; Surendra Kumar Sharma; Keertan Dheda
Journal:  Clin Infect Dis       Date:  2011-12-01       Impact factor: 9.079

2.  Plasma drug activity assay for treatment optimization in tuberculosis patients.

Authors:  Scott K Heysell; Charles Mtabho; Stellah Mpagama; Solomon Mwaigwisya; Suporn Pholwat; Norah Ndusilo; Jean Gratz; Rob E Aarnoutse; Gibson S Kibiki; Eric R Houpt
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

3.  Rapid detection of bacterial resistance to antibiotics using AFM cantilevers as nanomechanical sensors.

Authors:  G Longo; L Alonso-Sarduy; L Marques Rio; A Bizzini; A Trampuz; J Notz; G Dietler; S Kasas
Journal:  Nat Nanotechnol       Date:  2013-06-30       Impact factor: 39.213

Review 4.  Pharmacologic considerations in use and development of antituberculosis drugs.

Authors:  Geraint Davies
Journal:  Cold Spring Harb Perspect Med       Date:  2014-09-18       Impact factor: 6.915

5.  Phase II dose-ranging trial of the early bactericidal activity of PA-824.

Authors:  Andreas H Diacon; Rodney Dawson; Jeannine du Bois; Kim Narunsky; Amour Venter; Peter R Donald; Christo van Niekerk; Ngozi Erondu; Ann M Ginsberg; Piet Becker; Melvin K Spigelman
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

Review 6.  Transmission of drug-resistant tuberculosis in HIV-endemic settings.

Authors:  Palwasha Y Khan; Tom A Yates; Muhammad Osman; Robin M Warren; Yuri van der Heijden; Nesri Padayatchi; Edward A Nardell; David Moore; Barun Mathema; Neel Gandhi; Vegard Eldholm; Keertan Dheda; Anneke C Hesseling; Valerie Mizrahi; Roxana Rustomjee; Alexander Pym
Journal:  Lancet Infect Dis       Date:  2018-12-13       Impact factor: 25.071

7.  Suitability of Xpert MTB/RIF and genotype MTBDRplus for patient selection for a tuberculosis clinical trial.

Authors:  Sven O Friedrich; Amour Venter; Xavier A Kayigire; Rodney Dawson; Peter R Donald; Andreas H Diacon
Journal:  J Clin Microbiol       Date:  2011-06-08       Impact factor: 5.948

8.  Time to detection of Mycobacterium tuberculosis as an alternative to quantitative cultures.

Authors:  C M Bark; A Okwera; M L Joloba; B A Thiel; J G Nakibali; S M Debanne; W H Boom; K D Eisenach; J L Johnson
Journal:  Tuberculosis (Edinb)       Date:  2011-02-25       Impact factor: 3.131

9.  Xpert MTB/RIF as a measure of sputum bacillary burden. Variation by HIV status and immunosuppression.

Authors:  Colleen F Hanrahan; Grant Theron; Jean Bassett; Keertan Dheda; Lesley Scott; Wendy Stevens; Ian Sanne; Annelies Van Rie
Journal:  Am J Respir Crit Care Med       Date:  2014-06-01       Impact factor: 21.405

10.  Association of Xpert MTB/RIF Cycle Threshold Values with Tuberculosis Treatment Outcomes.

Authors:  Matheus de Matto Pires; Giovana Rodrigues Pereira; Márcia Silva Barbosa; Natan José Dutra Dias; Carina Secchi; Jociane Saldanha Hoff; Denise Rossato Silva
Journal:  Lung       Date:  2020-10-31       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.